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Frontotemporal dementia (FTD) and other tauopathies characterized by focal brain neurodegeneration and pathological accumulation of
proteins are commonly associatedwith taumutations. However, themechanism of neuronal loss is not fully understood. To identifymo-
lecular events associated with tauopathy, we studied induced pluripotent stem cell (iPSC)-derived neurons from individuals carrying the
tau-A152T variant.We highlight the potential of in-depth phenotyping of human neuronal cell models for pre-clinical studies and iden-
tification of modulators of endogenous tau toxicity. Through a panel of biochemical and cellular assays, A152T neurons showed accu-
mulation, redistribution, and decreased solubility of tau. Upregulation of tau was coupled to enhanced stress-inducible markers and
cell vulnerability to proteotoxic, excitotoxic, and mitochondrial stressors, which was rescued upon CRISPR/Cas9-mediated targeting
of tau or by pharmacological activation of autophagy. Our findings unmask tau-mediated perturbations of specific pathways associated
with neuronal vulnerability, revealing potential early disease biomarkers and therapeutic targets for FTD and other tauopathies.
INTRODUCTION
Frontotemporal dementia (FTD) refers to a group of
neurodegenerative diseases caused by focal but progressive
neuronal loss, astrogliosis, and spongiosis in the frontal
and temporal cortices associated with abnormal intracel-
lular accumulation of proteins, most commonly tau or
TDP43 (TAR DNA-binding protein 43) (Karageorgiou and
Miller, 2014; Neumann et al., 2015). Currently there are
no effective disease-modifying therapies for FTD, making
the treatment and prevention of FTD an area of significant
unmet medical need.
Tau is expressed ubiquitously in the brain and locates
predominantly in neuronal axons, where it regulates
microtubule polymerization and guides the transport of
proteins and organelles (Kosik et al., 1989; Morris et al.,
2011). Alternative splicing ofMAPTexons 2, 3, and 10 orig-
inates six tau isoforms that differ from one another by
29- or 58-amino-acid inserts at the N terminus, and by
the presence of either three (3R-tau) or four (4R-tau) tan-
dem-repeat sequences at the C terminus. Tau function
and localization are regulated by post-translational modifi-
cations (PTMs); for example, phosphorylation, acetylation,
and proteolysis (Johnson and Stoothoff, 2004; Min et al.,
2010; Wang et al., 2009). In FTD, sporadic or autosomal
dominant forms caused by MAPT mutations, inclusions
containing hyperphosphorylated tau (P-tau) are detected
within neurons and glia of affected brain regions.
Although these inclusions are key pathological features,
the events leading to neuronal loss may start even earlier,
but the tau species and precise molecular events causing
cell death are poorly understood. Therefore it is crucial to
investigate the early molecular events of disease, such as
alterations in tau biochemistry and affected cellular path-
ways (Gerson et al., 2014; Johnson and Stoothoff, 2004).
In this context, human induced pluripotent stem cell
(iPSC)-derived neurons allow exploring themolecular basis
of tau pathogenesis in a disease-relevant genetic back-
ground (Ehrlich et al., 2015; Haggarty et al., 2016; Iovino
et al., 2015).
Here, we investigated the underlying molecular and
cellular mechanisms of pathogenicity associated with the
rare tau variant A152T in a human neuronal context.
Although the role of tau A152T in disease is still debated,
it has been shown to affect tau function and PTMs,
promote oligomerization and postmortem detection of
inclusions, cause neuronal dysfunction independent of
aggregation and neuroinflammation in animal models,
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and increase significantly the risk for FTD and other neuro-
degenerative diseases (Coppola et al., 2012; Kara et al.,
2012; Labbe et al., 2015; Lee et al., 2013; Maeda et al.,
2016; Decker et al., 2016; Pir et al., 2016; Sydow et al.,
2016). We utilized iPSCs derived from A152T carriers and
derived neural progenitor cells (NPCs) and differentiated
neuronal cells (Figure 1A). These cells represent ex vivo
models of human neurons, with tau expression at endoge-
nous physiologically relevant levels and in the context of
the genomic background associated with disease. Overall,
our results reveal potential targets for disease-modifying
therapeutics to affect FTD and other tauopathies.
RESULTS
Human iPSC Lines
Cells from two individuals carrying the MAPT het-
erozygous variant A152T (c.1407G > A; NCBI RefSeq
NM_001123066; rs143624519) were studied. The first indi-
vidual was diagnosed with a form of FTD, progressive
supranuclear palsy, at the time of skin biopsy (FTD19, Table
S1), whose iPSCs were generated using standard retroviral
vectors and the Yamanaka factors OCT3/4, SOX2, KLF4,
and c-MYC (Biswas et al., 2016). The second was an asymp-
tomatic individual (Tau6, Table S1) whose iPSCs and
neuronal phenotypes have been in part characterized by
Fong et al. (2013). Two age-matched individuals were also
included as non-mutant controls: 8330-8 (Sheridan et al.,
2011) and CTR2-L17 (Almeida et al., 2012). Two iPSC
clones from the first A152Tcarrier (19-L3, 19-L5), one clone
from the second A152T carrier (Tau6-1), and two control
iPSC clones (8330-8 and CTR2-L17) were selected for
further studies (Table S1).
All iPSCs had typical characteristics of PSCs (Biswas
et al., 2016; Fong et al., 2013), including: colony-type
morphology; expression of the stem cell surface marker
SSEA-4 and pluripotency transcription factors OCT4/
POU5F1 and NANOG (Figure S1A); elevated expression of
endogenous OCT4/POU5F1, NANOG, and the zinc-finger
protein pluripotency marker ZFP42/REX1, relative to the
corresponding fibroblasts (Figure S1B); and ability for iPSC
in vitro formation of embryoid bodies (EBs) and sponta-
neous differentiation of EBs into the three germ layers ecto-
derm (TUJ1 expression), mesoderm (SMA expression), and
endoderm (AFP expression) (Figure S1C) (Itskovitz-Eldor
et al., 2000). Sanger sequencing of the MAPT locus
confirmed the c.1407G > A mutation in A152T iPSCs (Fig-
ure S1D). Preservation of normal karyotype was confirmed
(Figure S1E). Based on cell proliferation, morphology, and
ability to remain undifferentiated in culture over >50 pas-
sages, therewere no qualitative differences between control
and A152T iPSCs.
Derivation and Characterization of Human NPCs
NPC lines were generated from iPSCs through isolation of
neural rosettes (Nemati et al., 2011; Ungrin et al., 2008)
(Table S1). Newly generated NPCs were immunopositive
for the neural stem cell markers Nestin, SOX2, and Musa-
shi-1, and the neuroepithelial marker PAX6 (Figure 1B),
and were maintained in proliferative state under defined
growth media with EGF (epidermal growth factor) and
FGF (fibroblast growth factor ) (Figure 1A) (Nemati et al.,
2011; Sheridan et al., 2011; Yuan et al., 2011). Based on pro-
liferation, cell morphology, and viability, there were no
qualitative differences between control and A152T NPCs
(Figure 1B).
NPC Differentiation into Neurons
Based on an initial time-course analysis of NPC differentia-
tion (Figures S2A–S2F), we examined cortical and synaptic
markers in 5-week neurons from two control and two
A152T lines. Both control and A152T neurons expressed
markers of the cortical layers II–VI, with some variability
between cell lines (Figure 1C) that was not correlated with
MAPT genotype (Figure S2G), and comparable overall with
a human anterior cingulate cortex (ACC) sample. Expres-
sion of cortical markers was also confirmed by immuno-
fluorescence (IF) imaging of TBR1-, FEZF2-, CTIP2-, and
FOXG1-positive neurons, with highest detection in the nu-
cleus and cell body (Figures 1EI–1EIV). Expression of synap-
tic proteins PSD95, SYN1, and SYPwas also detected at com-
parable levels inallneuronal cells (Figures 1DandS2H),with
appreciable detection in neuronal processes but greater
detection in the cell body, as expected at an early stage of
neuronal maturity (Figures 1EV and 1EVI). NeuN is a
neuronal-specific nuclear/perinuclear protein and MAP2 is
a microtubule-associated protein, both utilized as neuronal
markers (Figures 1D and 1EVIII). The diversity of neuronal
cell types obtained fromNPC differentiation was examined
based on expression of specific markers. We detected
glutamatergic neurons, which are highly affected in FTD
(VGLUT1, Figures 1EVII and S3) (Huey et al., 2006), as well
as cholinergic, GABAergic, dopaminergic/adrenergic, and
serotonergic neurons, in addition to glia, with no detection
of neural crest or cardiomyocyte lineage cells (Figure S3).
These results revealed that NPC-differentiated cells
display neuron-specific morphology, and expression of
protein markers reminiscent of in vivo neurogenesis and
human cortical neurons. The variability captured between
cell lines (Figures 1C and 1D) was mostly due to inherent
differences between iPSC-derived clonal lines and was not
correlated with MAPT genotype (Figures S2G and S2H).
Upregulation of Tau in A152T Neurons
FTD-associated MAPT mutations, including the variant
A152T, have been shown to promote accumulation of tau
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Figure 1. Human iPSC-Derived NPCs, and Synaptic and Cortical Markers in NPC-Derived Neurons
(A) Summary of the experimental strategy followed. See also Figure S1.
(B) Bright-field and IF analysis of NPC markers (green) in control and A152T lines. Scale bar, 100 mm.
(C and D) Western blot analysis of cortical layers II–III, V, and VI markers (C) and synaptic proteins (D), in 5-week control and A152T
neurons. Human ACC is a positive control for cortical markers. GAPDH is the loading control. Samples ran in the same blot and are cropped
for clarity (nR 3 independent experiments). See also Figure S2.
(E) IF analysis of cortical (I–IV), synaptic (V–VI), glutamatergic (VII), and neuronal (VIII) markers (red) in 5-week neurons (represen-
tative of control and A152T). Dotted insets correspond to zoomed-in images. Scale bars, 20 mm. See also Figure S3.
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and neurodegeneration (Kara et al., 2012; Lee et al., 2013).
To explore whether this is an early disease-relevant molec-
ular event in A152T neurons, we started by examining tau
protein levels and PTMs. To this end, we utilized three NPC
lines derived from the FTD19 A152T carrier (19-L3-RC3,
19-L5-RC6, and 19-L5-RC7), two NPC lines from the Tau6
A152T carrier (Tau6-1-RC1 and Tau6-1-RC2), and three
control NPC lines (8330-8, 8330-8-RC1, and CTR2-L17-
RC2) (Table S1).
We first performed a time-course analysis of tau levels
by western blot between proliferative state (week 0) and
5 weeks of differentiation, by employing a panel of seven
tau and P-tau antibodies. By comparing averaged tau levels
between controls and A152T lines, we detected a time-
dependent increase in total tau levels (TAU5 and DA9 anti-
bodies), with a more rapid tau upregulation in A152T neu-
rons relative to control cells at 5 weeks of differentiation
(Figures 2A–2C). These antibodies report on total protein
independently of PTMs, which, together with alternative
splicing isoforms, give rise to distinct molecular weight
bands (Figure 2A, blue arrows). Recombinant human tau,
consisting of a ladder of six tau isoforms without PTMs,
was also included in the analysis to guide interpretation
of band pattern, even though equivalent migration does
not report on a particular endogenous tau isoform, given
endogenous tau PTMs. TAU1 antibody that recognizes a
form of non-P-tau (non-P-S199/S202/T205) corroborated
overall tau upregulation in A152T neurons (Figures 2A
and 2D). Further individual analysis of all cell lines at
5 weeks of differentiation revealed that, whereas FTD19-
derived A152T neurons showed an upregulation of total
tau, Tau6-1-derived neurons’ total tau levels were more
comparable with control after the same period of differen-
tiation (Figures S4A and S4B).
Next, P-tau was examined with the antibodies AT8
(P-Ser202/Thr205), AT180 (P-Thr231/Ser235), PHF1
(P-Ser396/Ser404), and S396 (P-Ser396), which recognize
phospho-epitopes associated with autosomal dominant
forms of tauopathy (Davies, 2000; Goedert et al., 1995).
The increase in P-tau levels was also time dependent
and, whether analyzed between averaged controls versus
A152T lines (Figures2E–2IandS4B inset)or individually (Fig-
ures S4A and S4B), all A152T neurons showed an upregula-
tion of P-tau relative to controls. In particular, AT8 and
AT180 tau were barely detected in control neurons (Figures
2F and2G).OnlyPHF1andS396 antibodies revealed tau spe-
cies of highmolecular weight (HMW; >250 kDa) with speci-
ficity toA152Tneurons (green arrows in Figures 2E and S4A),
indicating the presence of oligomeric, hyper-P-tau at
the Ser396/Ser404 epitope. Even with some variability
among clonal lines, our findings suggest tau upregulation
in A152T neurons, particularly in the form of P-tau (Figures
2E–2I and S4B). Semi-quantitative RT-PCR analysis revealed
that MAPT expression was constant between control and
A152T neurons (total MAPT, Figures S4C and S4D), and
that 3R- and 4R-tau expression was also constant across cell
lines,withhigher 3R-tau levels, consistentwith the immatu-
rity of these 5-week neurons (Figures S4C and S4E) (Stein
et al., 2014). These results suggest that upregulation of tau
is a result of protein accumulation rather than altered gene
expression. Subsequent studies are shown at 5 weeks of dif-
ferentiation, unless noted otherwise, but all phenotypes
were also validated up to 20 weeks of differentiation (not
shown).
We next utilized IF to examine the subcellular distribu-
tion of tau and P-tau. A152T neurons, in particular
FTD19-derived neurons, showed a stronger signal for total
tau K9JA antibody in the cell body and neuronal processes
relative to control (red in Figures 3I–3V). The distinction
between A152T and control neurons was even more accen-
tuated for P-tau PHF1 staining, which showed a weaker
signal in control neurons, being almost absent in cell
bodies, whereas A152T neurons showed strong PHF1 stain-
ing in cell body and neuronal processes (red in Figures 3VI–
3X). Upon co-staining of tau (K9JA) and P-tau (PHF1), we
observed a higher PHF1-to-K9JA (green-to-red) relative
intensity in A152T neurons, with a stronger PHF1 signal
in the cell body and neuronal processes of A152T neurons
relative to control (Figures 3XI–3XV).We did not, however,
detect foci-like tau staining, reminiscent of tau aggregates
or tangles, and neurons were Thioflavin-S negative (not
shown). Due to the high density of neuronal processes in
these cultures, we were unable to use automated micro-
scopy to accurately quantify subcellular tau levels.
Collectively, these results suggest that an early marker
of A152T pathogenesis is an early and time-dependent
Figure 2. Time-Dependent Upregulation of Tau in A152T Neurons
(A and E) Total tau (A) and P-tau (E) expression by western blot analysis of up to 5-week differentiated neurons in control and A152T cell
lines. Far-right panels show recombinant tau ladder (six tau isoforms, no PTMs); GAPDH is the loading control (n R 3 independent
experiments). Arrows indicate bands quantified: blue for bands with corresponding migration to the tau ladder, green for HMW bands.
Samples ran in same blot as far as possible.
(B–D and F–I) Semi-quantitative analysis of western blots in (A) and (E). Band intensities in a.u. relative to GAPDH, averaged (Avrg) across
genotype (controls/gray, A152T/black) ± SEM. Two-way ANOVA and Bonferroni post test, n R 3 independent experiments: ns, not
significant (p > 0.05); *p < 0.05, **p < 0.01.
See also Figure S4.
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accumulation of tau, predominantly in the form of P-tau
and oligomeric P-tau. IF corroborated the accumulation
of tau/P-tau in A152T neurons, further revealing increased
P-tau in neuronal processes and cell body of A152T
neurons, consistent with somatodendritic redistribution,
both important pathophysiological features of tauopathy,
detected here as an early phenotype in patient-derived neu-
rons in vitro (de Calignon et al., 2012; Fong et al., 2013; Li
et al., 2011; Sydow et al., 2016).
Quantitative Analysis of Tau in Human Neurons by
Mass Spectrometry
To corroborate our antibody-based results we employed
FLEXITau, a mass spectrometry (MS)-based targeted assay
for absolute quantification of tau protein levels and PTMs
(Mair et al., 2016). A schematic of this methodology is
shown in Figure 4A, and in-depth details have been
described (Mair et al., 2016; Singh et al., 2009). FLEXITau
absolute quantification of tau in control (8330-8-RC1)
and A152T (19-L5-RC6) neurons at 5, 12, and 20 weeks
of differentiation revealed upregulation of tau in A152T
neurons, which was more pronounced at 20 weeks of dif-
ferentiation (2.5-fold relative to control, average 28.5
fmol/mg and 11.4 fmol/mg protein lysate, respectively)
(Figure 4B). Notably, the levels of tau in control neurons
reached a plateau after 12 weeks, whereas A152T neurons
showed a linear increase in tau levels up to 20 weeks
of differentiation (Figure 4B, R2 = 0.999; not shown),
again indicative of aberrant tau accumulation in A152T
neurons.
Differential Expression of Non-mutant and A152T Tau
Given the lack of variant-specific antibodies to date, all
studies of expression of endogenousmutant tau have relied
on the inference that the mutated allele is expressed. How-
ever, this hindrance precludes gaining an understanding of
the ratio between non-mutant and mutant protein levels
and misinterpretation of total protein levels, because
gene mutations can alter protein stability and biochemical
properties. Therefore, we used a targeted MS approach
to measure non-mutant and variant tau protein levels
in control and A152T neurons (LysC digest, Figure 4A).
Shotgun tandem MS (MS/MS) analysis from LysC-digested
control and A152T neurons identified the peptides 151IAT
PRGAAPPGQK163 (non-mutant) and 151ITTPRGAAPP
GQK163 (A152T) by specific peptide fragment spectra (Fig-
ure S5). For quantification of these peptides, we developed
a targeted selected reaction monitoring (SRM) assay (Sup-
plemental Experimental Procedures), which showed that
in A152T neurons the levels of A152T tau are higher
(56.6%) than non-mutant tau (43.4%), and this ratio
stayed constant over the time points analyzed (Figure 4C),
even though overall levels of total tau increased (Figure 4B).
This is the first demonstration and quantification of allele-
specific expression of a tau variant protein in a human
iPSC-derived neuronal model.
Tau PTMs and Isoforms by Mass Spectrometry
FLEXITau MS analysis also enables the characterization of
MAPT splicing and tau PTMs (Mair et al., 2016). This strat-
egy relies on the quantification of unmodified tau peptides
in a cell lysate relative to spiked-in stable isotope-labeled
unmodified peptides derived from heavy-labeled tau pro-
tein. A reduction in cell lysate-measured light peptides
is evidence of a ‘‘modification’’ in the endogenous tau
peptide, and this modification can be a PTM, alternative
splicing, or a mutation. We employed global FLEXITau
analysis on 5-week neurons, using both trypsin and LysC
samples to maximize sequence coverage (Figure 4A). The
regions with the highest ‘‘modifications’’ were the exons
that undergo alternative splicing (E2, E3, E10; Figure 4D).
Within the sensitivity of our MS assay, the peptides
Figure 3. Upregulation of Tau in A152T
Neurons by IF Analysis
Total tau (K9JA), P-tau (PHF1), and MAP2
by IF in control and A152T 5-week neurons.
Dotted insets correspond to zoomed-in im-
ages shown on the right. Scale bars, 50 mm.
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corresponding to E2 and E3 were not detected, whereas
E10 (4R-tau) was detected by one peptide (Figure 4D),
corroborating gene-expression analysis (Figures S4C and
S4E) and predominance of the 0N3R isoform. FLEXITau
also detected ‘‘modified’’ peptides within the proline-rich
region and the C-terminal tail, probably corresponding
to PTMs. The peptides harboring Ser202/Thr205 (AT8),
Thr231/Ser235 (AT180), and Ser396/Ser404 (PHF1) epi-
topes showed a decrease in unmodified peptides, i.e., an
increase in ‘‘modified’’ epitopes in A152T neurons relative
to control (p = 0.013), consistent with increased P-tau (Fig-
ure 4D). As expected, in A152T neurons the non-mutant
(unmodified) peptide that covers the A152 site (151IAT
PRGAAPPGQK163) was only 47.5% of the corresponding
peptide in control neurons, as the remaining ‘‘modified’’
peptide harbors to A152T variant (Figure 4D).
One possible mechanism for the variant A152T to alter
tau function (Derisbourg et al., 2015) would be by
creating a new threonine (Thr/T) P-site. To test this, we
attempted to quantify the P-peptide 151IpTTPRGAAPP
GQK163 by SRM analysis, using a synthetic heavy P-pep-
tide as a reference. We were unable to detect the endoge-
nous light counterpart within the sensitivity range of our
SRM assay (as low as 2.5 fmol/mL of endogenous tau, not
shown), suggesting that in human iPSC-derived neurons,
the variant A152T is unlikely to create a new phosphory-
lation site or, if it does, it is phosphorylated to less than
2.5% occupancy.
Figure 4. Tau Profile by MS Analysis
(A) Workflow for preparation of control (8330-8-RC1) and A152T (19-L5-RC6) samples for MS analysis.
(B) Quantification of total endogenous tau by FLEXITau. Shown is average tau in fmol/mg of protein lysate ± SD (n = 3, except n = 2 for
week 20, see Experimental Procedures).
(C) Relative amount of endogenous non-mutant tau and A152T tau in control and A152T neurons (mean ± SD, n = 3, except n = 2 for week
20, see Experimental Procedures).
(D) Global quantitative peptide profile by FLEXITau, relative to full-length 2N4R-tau. Shown is the normalized amount of unmodified
peptides relative to heavy tau protein standard (mean ± SD, n = 3 independent experiments). *p < 0.05, Student’s t test.
See also Figure S5.
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Reduced Tau Solubility in A152T Neurons
To determine whether accumulation of P-tau led to the for-
mation of protein species of reduced solubility, a hallmark
of tauopathy, we tested tau protein differential solubility to
TritonX-100 and SDS detergents (Guo and Lee, 2011, 2013;
Kfoury et al., 2012). A152T neurons showed significantly
more accumulation of Triton-insoluble total tau (TAU5)
and P-tau (AT8, S396), i.e., SDS-fraction tau (S, Figure 5A).
The HMW species (>250 kDa) detected by the P-tau S396
antibody showed amixture of detergent-soluble and -insol-
uble tau in A152T neurons, but only Triton-soluble tau in
control neurons. When comparing only the insoluble frac-
tions (S), A152T neurons showed a preferential accumu-
lation of P-tau, which was particularly accentuated in
FTD19-derived neurons (Figure 5B). These results suggest
that accumulation of tau in A152T neurons leads to the for-
mation of species of reduced solubility, which is likely to
negatively affect cellular function.
Affected Proteostasis in FTD Neurons
We examined whether upregulation of tau in A152T neu-
rons affected proteostasis, which is kept by the concerted
function of multiple pathways (Figure 6A), including the
heat-shock response (HSR) and the ER and mitochondrial
unfolded protein responses (UPR) that upregulate expres-
sion of molecular chaperones and other factors to prevent
aberrant accumulation of proteins, and the ubiquitin pro-
teasome system (UPS) and autophagy-lysosomal pathways
responsible for clearance of these proteins (Balch et al.,
2008; Wong and Cuervo, 2010). We asked whether these
pathways were affected in A152T neurons by measuring
pathway-specific components (Figure 6A, in blue). We
examined 8-week differentiated neurons to take advantage
of time-dependent accumulation of tau.
Relative to control, A152T neurons showed an increase
in polyubiquitinated proteins (UBI1), which accumulate
when UPS is disrupted, as well as an upregulation of
autophagy markers (LC3B-II, ATG12/5, SQSTM1/p62,
LAMP1, and LAMP2a), revealing activation of autophagy
in A152T neurons (Figures 6B, 6F, 6D, and 6I). In contrast,
there was no significant HSP70 chaperone family (HSP70,
CHIP, HIP, and HOP) or HSP90 upregulation, suggesting
no HSR induction (Figures 6C and 6G). To examine oxida-
tive stress, we measured the levels of carbonylated proteins
that accumulate in the cell by excessive protein oxidation
(Figure 6D) (Dalle-Donne et al., 2003). A152T neurons
showed a modest increase in stable 2,4-dinitrophenylhy-
drazone (DNP) proteins, suggesting disruption of proteo-
stasis leading to oxidative stress (p = 0.06, Figure 6H).
Finally, we examined UPR bymeasuring the ratios between
the phospho-active forms and total levels of PERK, eIF2a,
and IRE1a (Stutzbach et al., 2013), and the downstream tar-
gets CHOP and ER-HSP70 BiP (Figure 6A). Our results
showed P-eIF2a/eIF2a and P-IRE1a/IRE1a upregulation in
A152T neurons, with further increase in BiP and CHOP
levels (Figure 6J). Even though we did not detect upregula-
tion of P-PERK/PERK, CHOP is a downstream target of
P-PERK and P-eIF2a, and transcriptional regulation cannot
be excluded. Altogether, these results suggest that protein
clearance and UPR are the most affected proteostasis path-
ways at the early stage of tau accumulation in an A152T
iPSC-derived neuronal model.
Selective Vulnerability of A152T Neurons to Stress
Based upon the premise that tauopathy results from time-
dependent cumulative cell damage due to buildup of toxic
proteins, we asked whether accumulation of tau in A152T
neurons was deleterious. If so, by ‘‘adding insult to injury’’
neurons affected by tau accumulation should have lower
capacity to survive additional stress (Frost et al., 2015; Gi-
dalevitz et al., 2010).With the goal of also identifying path-
ways that may be compromised by tau pathology, we
treated 8-week neurons with pathway-specific chemical
stressors and compared cell viability between A152T and
control neurons (Figure 7A). These ‘‘stressors’’ included
environmental toxins that inhibit the mitochondrial elec-
tron transport chain (ETC) complex I (rotenone and pieri-
cidin A) (Hoglinger et al., 2005; Hollerhage et al., 2014);
Figure 5. Detection of Insoluble Tau in
A152T Neurons
(A) Western blot analysis of total tau
(TAU5) and P-tau (S396, AT8) in Triton X
(T)-soluble and Triton-X-insoluble SDS (S)
fractions from 5-week neurons. GAPDH is
the loading control.
(B) Semi-quantitative analysis of S-fraction
band intensities from (A), relative to GAPDH
in T-fraction (AU, arbitrary units). Values
averaged between control, FTD19, and Tau6
lines (±SEM, n R 3 independent experi-
ments; *p% 0.05, ***p% 0.001, Student’s
t test).
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excitotoxic agonists of the glutamatergic AMPA and/or
NMDA receptors (glutamate and NMDA) (Dong et al.,
2009; Huey et al., 2006); and proteotoxic proteasome in-
hibitors (MG132 and epoxomicin) and A-b(1–42) amyloid
peptide (a predominant component of amyloid plaques
in Alzheimer’s disease) (Roberson et al., 2007). To identify
conditions whereby control and A152T neurons showed
different survival, we started by performing a dose-depen-
dent study in which compounds were added to neuronal
cultures at different concentrations for 24 hr and cell
viability was measured (Figures S6A–S6G). At the concen-
trations shown in Figure 7, stressor compounds had mini-
mum impact in control neurons but caused a significant
reduction in viability (<50% viable) of A152T neurons
Figure 6. Enhanced Stress Markers in A152T Neurons
(A) Simplified representation of proteostasis pathways responsive to proteotoxic stress (blue denotes components measured).
(B–J) Western blot and semi-quantitative analysis, in 8-week control and A152T neurons, of: (B and F) polyubiquitinated (UBI1), macro-
autophagy (LC3B, SQSTM1/p62, ATG12-ATG5), and chaperone-mediated autophagy (LAMP1, LAMP2a) proteins; (C and G) molecular
chaperones (HSP70, HSP90) and HSP70 co-chaperones (CHIP, HIP, HOP) of the HSR; (D and H) polycarbonylated proteins (DNP-derived);
(E and J) UPR activation of PERK, eIF2a, and IRE1a, and downstream targets CHOP and BiP; (D and I) tau (DA9) and P-tau (PHF1). Shown is
mean band intensity (±SD) relative to GAPDH; n = 3 independent experiments. Student’s t test: *p < 0.05, **p < 0.01, ***p < 0.001; ns, not
significant.
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Figure 7. Increased Vulnerability to Stress in A152T Neurons Is Tau Dependent
(A) Overview of the stress vulnerability tests done in 8-week neurons (a) using high doses of stress, (b) pre-treating neurons with the
autophagy inducer rapamycin, or by testing genetically engineered MAPT-Kd neurons.
(B, D, and F) Cell viability of 8-week neurons, treated with compounds for 24 hr. Values represent percent viability (±SEM) relative to
vehicle-treated neurons. *p < 0.05, **p < 0.01, ***p < 0.001, two-way ANOVA and Bonferroni post test (nR 3 independent experiments).
(C, E, and G) IF analysis of neuronal integrity of control (CTR2-L17-RC2) and A152T (19-L3-RC3) neurons upon 24-hr treatment, based on
MAP2/NeuN staining. Scale bars 50 mm.
(legend continued on next page)
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(Figures 7B, 7D, and 7F). These effects were also detected by
IF of MAP2 and NeuN as markers of neuronal integrity,
where A152T neurons incubated with mitochondrial ETC
inhibitors (Figure 7C), excitotoxins (Figure 7E), or proteo-
toxins (Figure 7G) showed selective cell loss. These results
revealed a phenotype of cellular toxicity suggesting that
tau/P-tau accumulation in A152T neurons is associated
with increased stress vulnerability, consistent with the
observation of altered stress-inducible markers (Figure 6).
Vulnerability of A152T Neurons to Stress Is Tau
Dependent
To test the direct correlation between upregulation of tau in
A152T neurons and increased vulnerability to stress, we
examined whether downregulation of the ‘‘toxic’’ tau
would be sufficient to rescue viability. First, we genomically
engineered the A152T cell line 19-L5-RC6 with CRISPR/
Cas9 constructs for targeting and disrupting expression of
the MAPT gene (Hsu et al., 2014; Shalem et al., 2014).
The resulting cell lines (19-L5-RC6;MAPT-Kd) revealed a
sharp downregulation (R80%) of tau protein upon differ-
entiation (Figures S6K and S6L), without detectable effect
on neuronal integrity (Figures S6M and S2A) or cellular
viability (Figure 7H). Remarkably, upon exposure to the
cellular stressors that revealed vulnerability of the parental
tau-A152T neurons, we observed a rescue of stress
vulnerability in 8-week 19-L5-RC6;MAPT-Kd3 neurons,
with viability increase to 90%–100%, similar to control
(Figure 7H).
Second, we utilized the mTOR (mammalian target of
rapamycin) inhibitor and autophagy activator rapamycin
(Berger et al., 2006; Ozcelik et al., 2013). In control neu-
rons, rapamycin downregulated tau by R50% via activa-
tion of the autophagy pathway, as shown by upregulation
of the autophagosome marker LC3B-II (Figures S7N–S7P).
We then pre-treated 8-week differentiated A152T neurons
with rapamycin (8 hr) before exposure to stressor com-
pounds (Figure 7A). Rapamycin-pre-treated A152T neurons
showed a significant increase in cell viability relative to un-
treated neurons (Figure 7I). Consistent with the level of tau
downregulation, rapamycin caused amilder but consistent
rescue of viability comparedwith genetic knockdown (50%
versus >80%, respectively).
Stress vulnerability tau dependence was further corrobo-
rated by testing the same stressors in 2-week neurons (Fig-
ures S6H–S6J), before tau accumulation, without a differ-
ence in survival between A152T and control neurons.
Altogether, these findings unequivocally demonstrate
that accumulation of tau in A152T neurons is coupled to
disruption of proteostasis and increased vulnerability to
stress, earlymolecular events leading to neurodegeneration
in tauopathy. Our study also demonstrates that endoge-
nous tau-mediated cellular stress can be rescued by com-
pounds that mediate tau clearance, which is of crucial
relevance for the use of this cellular model for the develop-
ment of therapeutics.
DISCUSSION
Human iPSC-derived neurons allow measurement of dis-
ease-relevant cellular and molecular phenotypes in a phys-
iologically and genomically relevant context, potentially
recapitulating the early stages of disease etiology, and allow
direct testing of therapeutic targets and small molecules in
a human neuronal environment (Almeida et al., 2012; Bili-
can et al., 2012; Ehrlich et al., 2015; Fong et al., 2013; Hag-
garty et al., 2016; Iovino et al., 2015; Wren et al., 2015). We
took advantage of this system to investigate the early
events of tau-A152T pathology that may be causal in
FTD. Our findings contribute tomounting evidence, across
studies of different tau mutations and across model sys-
tems, of tau-mediated molecular events associated with
neurodegeneration, toward the identification of relevant
therapeutic targets (Ehrlich et al., 2015; Fong et al., 2013;
Iovino et al., 2015; Maeda et al., 2016; Decker et al.,
2016; Pir et al., 2016; Sydow et al., 2016; Wren et al.,
2015). We biochemically profiled neurons derived from
control and A152T carriers, and report on a phenotyping
platform for tau regarding protein levels, PTMs, and
solubility. We demonstrate accumulation of endogenous
tau/P-tau in A152T human neurons by multiple powerful
methods. By western blot we found a significant upregu-
lation of P-tau in all A152T neurons, whereas total tau
upregulation was specific to the FTD19-derived neurons,
consistent with previous reports (Fong et al., 2013; Sydow
et al., 2016). This result might be a consequence of vari-
ability among individuals of the same MAPT genotype,
and possibly the clinical outcome, but only future analysis
of larger cohorts of cases could allow us to draw accurate
conclusions. By MS analysis we verified upregulation of
(H) Cell viability of 8-week neurons upon 24-hr treatment. The genetically engineered line MAPT-Kd3 (19-L5-RC6;MAPT-Kd3) showed
rescue of vulnerability to stress relative to A152T neurons. Percent viability (±SEM) is relative to vehicle-treated cells (100%). Two-way
ANOVA and Bonferroni post test: *p < 0.05, ***p < 0.001; ns, not significant (p > 0.05) (nR 3 independent experiments).
(I) Rescue of A152T neuronal (19-L5-RC6) vulnerability to stress [24 hr of rotenone, NMDA, and Ab(1–42)] by 8-hr pre-treatment
of neuronal cultures with rapamycin (RAP, 5 mM). Percent viability (±SEM) is relative to vehicle-treated cells (100%). Student’s t test:
*p < 0.05, **p < 0.01, ***p% 0.001; ns, not significant (p > 0.05) (nR 3 independent experiments).
See also Figure S6.
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absolute levels of endogenous tau in A152T neurons that
became accentuated with time. By targetedMS, we demon-
strated differential levels of tau A152T versus the non-
mutant form in A152T neurons, which is relevant to the
identification of ‘‘the toxic species.’’ Even though this ratio
(60% versus 40%, respectively) was constant during the
period of time tested (Figure 4C), the gradual increase in to-
tal tau (Figure 4B), suggests that this amount of tau-A152T
is sufficient to cause some imbalance that leads to overall
accumulation of tau.
By IF we detected an overall increase in tau in A152T neu-
rons, with particular accumulation of P-tau in the cell body,
consistent with somatodendritic redistribution of tau, as
described for tauopathies andAlzheimer’s disease (deCalig-
non et al., 2012; Fong et al., 2013; Li et al., 2011; Sydow
et al., 2016). We did not detect A152T-specific changes in
cell morphology, as reported in another A152T model
(Fong et al., 2013), which may be due to differences in
methodologies and line-specific variability. Nonetheless,
the overall conclusion of tau accumulation, somatoden-
dritic redistribution, and tau-mediated neuronal toxicity
in A152T cells was a common observation, unmasked
either by additional stress (Figure 7) or by genetic manipu-
lation (A152T homozygous line in Fong et al., 2013). Taken
together, these two studies are complementary by demon-
strating that even with technical variability, key aspects in
pre-clinical disease events were corroborated.
We also reveal here, for an FTD A152T proband-derived
neuronal culture, a decrease in tau solubility, again most
accentuated for P-tau. Although we did not detect tau
puncta-like aggregates per se, Triton X-insoluble tau and
the HMW species detected are consistent with oligomeric
species of reduced solubility. Based on our findings we pro-
pose a model in which accumulation of P-tau and oligo-
meric tau of reduced solubility are early disease-causal
phenotypes, consistent with other A152T animal models
demonstrating tau-mediated toxicity independent of ag-
gregation (Maeda et al., 2016; Pir et al., 2016).
To explore the mechanisms of tau-mediated toxicity, we
focused on specific proteostasis pathways shown previ-
ously to be involved in tauopathy, including the HSP70/
HSP90 chaperone machinery (Blair et al., 2013), UPR
markers (Stutzbach et al., 2013), mitochondrial function
and oxidative stress (Schulz et al., 2012), and autophagy
(Wang and Mandelkow, 2012). We report on disruption
of the UPS and autophagy pathways, in addition to UPR
and oxidative stress induction, in A152T neurons. Disrup-
tion of protein clearance is a strongmodel for tau-mediated
toxicity in neurodegeneration, and is consistent with the
observed accumulation of total tau protein. Also consistent
with our findings, a recent study identified alterations
of the endosomal-lysosomal pathway associated with
another taumutation (Wren et al., 2015); yet another study
identified LAMP1 and ubiquitin as cerebrospinal fluid
markers of neurodegeneration, reinforcing the value of
our system in the identification of tauopathy biomarkers
(Heywood et al., 2015). In turn, mounting evidence points
to UPR activation ‘‘in close connection with early stages of
tau pathology’’ (Abisambra et al., 2013; Stoveken, 2013),
and to mitochondrial dysfunction and vulnerability to
oxidative stress as common aspects in iPSC-derived models
of tauopathy (Ehrlich et al., 2015; Iovino et al., 2015).
Tau-mediated disruption of proteostasis was further
revealed by increased sensitivity of A152T neurons to
exogenous ‘‘stressors,’’ unveiling toxicity phenotypes and
pathways that may be affected in the early stages of tau
pathology, offering a powerful method for phenotypic
profiling of patient-derived neurons. Not all stressor com-
pounds tested affected neuronal viability (not shown),
revealing pathway-specific vulnerability. These pheno-
types were tau dependent as shown by CRISPR/Cas9-
mediated downregulation of MAPT expression in A152T
neurons, which rescued neuronal stress vulnerability
without affecting cell viability or integrity (Figures 7H
and S6M). Most importantly, we demonstrate that stress
vulnerability can be rescued pharmacologically by pre-
treating neurons with the autophagy activator rapamycin,
highlighting the value of this model for small-molecule
screening. This is the first time, in a human neuronal cell
context and with endogenous tau expression, that a com-
pound has been shown to clear tau and consequently
rescue toxicity. This result also further corroborates amodel
of tauopathy associated with disruption or inefficiency of
protein clearance.
The results presented here are consistent with the propo-
sition that the onset of cellular pathology in FTD occurs
earlier than clinicalmanifestations, whichhas been corrob-
orated by biomarker studies in Alzheimer’s disease (Jack
et al., 2013). By implementing a panel of biochemical
and cellular assays, and a toolbox of compounds that reveal
pathways affected by tau toxicity, we demonstrated the
power of phenotypic characterization of patient-derived
neuronal cells at the pre-clinical level, which is now
suitable for mechanistic studies across MAPT genotypes.
Finally, we show that endogenous tau phenotypes can be
pharmacologically rescued, proving the suitability of our
patient iPSC-derived neuronal model for screening thera-
peutic targets and disease-modifying agents relevant to
FTD and other tauopathies.
EXPERIMENTAL PROCEDURES
iPSC, NPC, and Neuronal Cultures
Reprogramming, characterization, and maintenance of iPSCs, and
NPC derivation have been described elsewhere (see Supplemental
Experimental Procedures) (Zhao et al., 2012). NPCs were cultured
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on polyornithine and laminin (POL)-coated plates, with DMEM/
F12-B27 media supplemented with EGF, FGF, and heparin, and
passaged with TrypLE (Life Technologies). Approval for work
with human subjects’ materials and iPSCs was obtained under
IRB-approved protocols at Massachusetts General Hospital/Part-
ners Healthcare (2009P002730) and University of California, San
Francisco (10-00234). Neural differentiation was achieved by
plating NPCs (passages 30–35) at a density of 50,000 cells/cm2
on POL plates, with DMEM/F12-B27 media only (no growth
factors), and with 1/2 medium change every 3–4 days.
Protein Analysis by Western Blot
Western blot analysis was performed using the Novex NuPAGE
SDS-PAGE Gel System (Invitrogen) and standard immunoblotting
techniques (see Supplemental Experimental Procedures).
LC-MS/MS Analysis
Absolute abundance of endogenous tau was determined using the
FLEX peptide light-to heavy (L/H) ratio as recently described (Mair
et al., 2016; Singh et al., 2009). The number of independent exper-
iments was three; however, due to inherent challenges with long-
termhuman neuronal differentiated cultures, there was a punctual
necessity to pool samples for enough protein material at 20 weeks,
for which n = 2 (Figures 4B–4D). See Supplemental Experimental
Procedures for Expression and Purification of Heavy FLEXITau
Standard, FLEXITau Sample Preparation and analysis, spectra
analysis, data processing, and FLEXITau liquid chromatography
(LC)-SRM measurements.
Analysis of Protein Solubility by Detergent
Fractionation
The analysis was performed according to published protocols (see
Supplemental Experimental Procedures).
MAPT Knockdown by CRISPR/Cas9 Genomic
Engineering
The MAPT gene locus was targeted by the Tau CRISPR/Cas9 KO
Plasmid (h) and Tau HDR Plasmid (h) (Santa Cruz Biotechnology
sc-400136/sc-400136-HDR) in 19-L5-RC6 NPCs, according to
the manufacturer’s instructions (see Supplemental Experimental
Procedures).
Compound Treatment and Viability Assays
Compound or vehicle alone was added directly onto the cellular
medium. Viability was measured with the Alamar Blue Cell
viability reagent (Life Technologies), according to the manufac-
turer’s instructions. Readingswere done in the EnVisionMultilabel
Plate Reader (PerkinElmer). For IF, fixed neurons image acquisition
was done with the IN Cell Analyzer 6000 Cell Imaging System (GE
Healthcare Life Sciences). For further details see Supplemental
Experimental Procedures.
SUPPLEMENTAL INFORMATION
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